Associate Professor, Medicine-Brigham and Women's Hospital, Harvard Medical School
Oncology
Dr. Levi A. Garraway, MD
|
|
Give Review
Doctor Levi A. Garraway, MD works in the field of Oncology. He graduated from Harvard Medical School. Harvard Medical School is one of the top medical schools in the US. Harvard Medical School is ranked 1 in research and 12 in primary care medicine He received awards:"Elected Member". Levi A. Garraway, MD is a published doctor. He published 100 publications, including: 'MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells.'
Publications
- MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in Cancer cells.
- Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets.
- A Functional Landscape of Resistance to ALK Inhibition in Lung Cancer.
- Re: Floris H. Groenendijk, Jeroen de Jong, Elisabeth E. Fransen van de Putte, et al. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Ex...
- Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
- ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors.
- RNF43 is frequently mutated in colorectal and endometrial Cancers.
- Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia.
- Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma.
- Genetic modifiers of EGFR dependence in non-small cell lung Cancer.
- Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma.
- Prostate Cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate Cancer.
- Prospective Enterprise-Level Molecular Genotyping of a Cohort of Cancer Patients.
- A Small Molecule That Binds and Inhibits the ETV1 Transcription Factor Oncoprotein.
- Assessing the clinical utility of Cancer genomic and proteomic data across tumor types.
- FGFR3 expression in primary and metastatic urothelial carcinoma of the Bladder.
- Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision Cancer medicine.
- Genomic analysis of head and neck squamous cell carcinoma cell lines and human Tumors: a rational approach to preclinical model selection.
- ARID1B is a specific vulnerability in ARID1A-mutant Cancers.
- Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck Cancer.
- Discovery and saturation analysis of Cancer genes across 21 tumour types.
- Reduced local mutation density in regulatory DNA of Cancer genomes is linked to DNA repair.
- Successful whole-exome sequencing from a prostate Cancer bone metastasis biopsy.
- Oncogenic and drug-sensitive NTRK1 rearrangements in lung Cancer.
- MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition.
- The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma.
- A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma.
- Processes and preliminary outputs for identification of actionable genes as incidental findings in genomic sequence data in the Clinical Sequencing Exploratory Researc...
- A melanocyte lineage program confers resistance to MAP kinase pathway inhibition.
- Re: Stoehr et al. Lack of evidence for frequent MED12 p.L1224F mutation in prostate tumours from Caucasian patients. J Pathol 2013; 230: 453-456.
- Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia.
- A survey of informatics approaches to whole-exome and whole-genome clinical reporting in the electronic health record.
- An interactive resource to identify Cancer genetic and lineage dependencies targeted by small molecules.
- Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers.
- Mutational heterogeneity in Cancer and the search for new Cancer-associated genes.
- Punctuated evolution of prostate Cancer genomes.
- Genomics-Driven Oncology: Framework for an Emerging Paradigm.
- Precision Oncology: An Overview.
- Epigenomic alterations in localized and advanced prostate Cancer.
- Lessons from the Cancer genome.
- BCL2A1 is a lineage-specific antiapoptotic Melanoma oncogene that confers resistance to BRAF inhibition.
- A Genome-Scale RNA Interference Screen Implicates NF1 Loss in Resistance to RAF Inhibition.
- ATARiS: Computational quantification of gene suppression phenotypes from multisample RNAi screens.
- Molecular archeology: unearthing androgen-induced structural rearrangements in prostate Cancer genomes.
- Highly Recurrent TERT Promoter Mutations in Human Melanoma.
- Attitudes of patients with Cancer about personalized medicine and somatic genetic testing.
- Discordant Cellular Response to Presurgical Letrozole in Bilateral Synchronous ER+ Breast Cancers with a KRAS Mutation or FGFR1 Gene Amplification.
- Absence of oncogenic canonical pathway mutations in aggressive pediatric rhabdoid Tumors.
- Mapping the hallmarks of Lung adenocarcinoma with massively parallel sequencing.
- High throughput mass spectrometry-based mutation profiling of primary uveal Melanoma.
- Resistance to EGFR blockade in colorectal Cancer: liquid biopsies and latent subclones.
- Concordance and Discordance in Tumor Genomic Profiling.
- A landscape of driver mutations in Melanoma.
- Sequence analysis of mutations and translocations across breast Cancer subtypes.
- High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes.
- Melanoma: from mutations to medicine.
- MicroSCALE Screening Reveals Genetic Modifiers of Therapeutic Response in Melanoma.
- Circumventing Cancer drug resistance in the era of personalized medicine.
- High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing.
- RAS Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors.
- Genomic sequencing of Colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion.
- Characterization of the DNA Copy-Number Genome in the Blood of Cutaneous T-Cell Lymphoma Patients.
- Detection of KIAA1549-BRAF Fusion Transcripts in Formalin-Fixed Paraffin-Embedded Pediatric Low-Grade Gliomas.
- The mutational landscape of head and neck squamous cell carcinoma.
- Functional genomics reveal that the serine synthesis pathway is essential in breast Cancer.
- Systematic investigation of genetic vulnerabilities across Cancer cell lines reveals lineage-specific dependencies in ovarian Cancer.
- Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling.
- High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing Tumors toward inhibition of the RAS/RAF/MEK signaling cascade.
- Clinical implications of the Cancer genome.
- Intronic miR-211 assumes the tumor suppressive function of its host gene in Melanoma.
- An integrated approach to uncover drivers of Cancer.
- Recurrent BRAF mutations in Langerhans cell histiocytosis.
- Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy.
- On or off target: mutations, models, and predictions.
- Integrative analysis of the Melanoma transcriptome.
- An oncogenic role for ETV1 in Melanoma.
- Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 Cancer cell line set.
- MEK1 mutations confer resistance to MEK and B-RAF inhibition.
- p85 Associates with unphosphorylated PTEN and the PTEN-associated complex.
- Oncogenic activating mutations are associated with local copy gain.
- AKT-independent signaling downstream of oncogenic PIK3CA mutations in human Cancer.
- PTR1-dependent synthesis of tetrahydrobiopterin contributes to oxidant susceptibility in the trypanosomatid protozoan parasite Leishmania major.
- Predicting drug susceptibility of non-small cell lung Cancers based on genetic lesions.
- Applications of genomics in Melanoma oncogene discovery.
- PTEN loss contributes to erlotinib resistance in EGFR-mutant lung Cancer by activation of Akt and EGFR.
- Profiling critical Cancer gene mutations in clinical tumor samples.
- Modeling genomic diversity and tumor dependency in Malignant melanoma.
- Assessing the significance of chromosomal aberrations in Cancer: methodology and application to glioma.
- A 2-Mb critical region implicated in the microcephaly associated with terminal 1q deletion syndrome.
- Integrative genomic approaches identify IKBKE as a breast Cancer oncogene.
- Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung Cancer mouse models.
- High-throughput oncogene mutation profiling in human Cancer.
- Malignant melanoma: genetics and therapeutics in the genomic era.
- Sensitive mutation detection in heterogeneous Cancer specimens by massively parallel picoliter reactor sequencing.
- Androgen-dependent regulation of Her-2/neu in prostate Cancer cells.
- Inferring loss-of-heterozygosity from unpaired Tumors using high-density oligonucleotide SNP arrays.
- From integrated genomics to tumor lineage dependency.
- Oncologists' and Cancer patients' views on whole-exome sequencing and incidental findings: results from the CanSeq study.
- Truncating PREX2 mutations activate its GEF activity and alter gene expression regulation in NRAS-mutant Melanoma.
Schools
Harvard Medical School
Massachusetts General Hospital
Conditions Treated
- Anemia
- Bladder Cancer
- Colorectal Cancer
- Gum Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Elected Member
Education
-
Brigham and Women's Hospital -
Massachusetts General Hospital -
Harvard Medical School
Hospital
-
Brigham and Women's Hospital -
Dana-Farber Cancer Institute
Helpful Reviews
Similar Doctors
|
|
Dr. Matthew B. Yurgelun, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Juan Godinez, MD |
|
|
Dr. Jennifer Gao, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jason S. Fisherman, MD
This Doctor is OpenDoctor Recommended.
|